Mode
Text Size
Log in / Sign up

Platelet-rich plasma therapy in knee osteoarthritis patients showed high prediction accuracy for pain reductionCan a simple injection predict who gets real pain relief from knee treatment?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note high prediction accuracy for PRP-induced pain reduction in knee osteoarthritis, but safety and efficacy remain uncertain due to study design.

This retrospective cohort study examined 102 patients diagnosed with knee osteoarthritis who underwent platelet-rich plasma (PRP) therapy. The primary objective was to assess the prediction accuracy for a clinically meaningful reduction in pain, defined as a decrease of at least 2 points on the Numerical Rating Scale (NRS) at the 6-month follow-up. No comparator group or control arm was reported in the study data.

The analysis yielded a prediction accuracy of 90.3% for the primary outcome. The area under the curve (AUC) was calculated at 0.862, suggesting strong discriminatory ability of the model. Additionally, the Cohen's kappa coefficient was 0.611, indicating moderate agreement between predicted and observed outcomes. Absolute numbers for these metrics were not reported.

Safety and tolerability data were not reported in the available evidence. No adverse events, serious adverse events, discontinuations, or specific tolerability metrics were provided. The study setting and publication details were not reported. Funding sources and potential conflicts of interest were not disclosed.

Key limitations include the retrospective nature of the design, the absence of a comparator group, and the lack of reported safety data. These factors prevent definitive conclusions about the causal efficacy or safety profile of PRP therapy. While the study provides a strong basis for introducing individualized therapeutic modalities in the management of osteoarthritis, clinicians should interpret these predictive metrics with caution due to the observational study design and incomplete reporting of safety outcomes.

Living with knee osteoarthritis means dealing with constant pain that can make walking or playing with your kids difficult. Many patients wonder if a specific injection will help or if they should just wait for surgery. This study focused on patients who received platelet-rich plasma therapy, a treatment that uses your own blood to help heal the joint. The main goal was to find out if we could accurately guess who would feel at least two points less pain on a standard scale after six months.

The researchers found that their prediction method was very accurate, correctly identifying the outcome in over 90% of cases. This suggests that looking at certain factors before the shot could help doctors decide who is most likely to benefit. While no serious safety problems were reported in this small group, the study only looked at 102 people. Because the group was small and the study design was retrospective, these results are promising but not yet a guarantee for every patient.

This work provides a strong basis for introducing individualized therapeutic modalities in the management of osteoarthritis. It means doctors might soon be able to tailor advice based on who is likely to respond well. However, because the evidence is limited to this specific group, it does not replace the need for personalized medical advice. Talk to your doctor about what these numbers mean for your specific situation.

What this means for you:
A new method can predict who gets pain relief from knee injections, but results are based on a small group of patients.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
ObjectiveThe purpose of the study is to predict clinical responses to platelet-rich plasma (PRP) therapy in patients with knee osteoarthritis (KOA) before treatment and to identify the crucial efficacy predictors.MethodsWe reviewed the multidimensional clinical data of 102 KOA patients who underwent PRP therapy with a retrospective approach, including anthropometrics and blood indices. We defined the response to treatment as a reduction in the Numerical Rating Scale (NRS) pain score of ≥2 at the 6-month follow-up. After comprehensive data preprocessing, including imputation, Yeo–Johnson transformation, standardization, and balancing via SMOTETomek, 33 clinical features were retained. We then created and verified multiple machine learning models using 10-fold cross-validation (CV) on a 70% training cohort. The most effective model was subsequently validated on the 30% test cohort, and feature contributions were interpreted using SHapley Additive exPlanations (SHAP) analysis.ResultsThe Gradient Boosting Classifier showed the best overall performance among all tested models. The final model achieved a prediction accuracy of 90.3%, an area under the curve (AUC) of 0.862, and a Cohen’s kappa coefficient of 0.611 on the test set, indicating high predictive consistency. The SHAP interpretability analysis revealed three biomarkers—osmotic pressure, lipoprotein(a) [Lp(a)], and uric acid—as the clinical factors most strongly associated with treatment response.ConclusionClinical character-based machine learning models are effective in predicting PRP therapy outcomes prior to treatment. Such results provide a strong basis for introducing individualized therapeutic modalities in the management of osteoarthritis.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.